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KRAS mutation leads to decreased expression of regulator
of calcineurin 2, resulting in tumor proliferation in
colorectal cancer
H Niitsu1, T Hinoi1,2, Y Kawaguchi1,3, K Sentani4, R Yuge5, Y Kitadai5, Y Sotomaru6, T Adachi1, Y Saito1,7, M Miguchi1,8, M Kochi1, H Sada1,
M Shimomura9, N Oue4, W Yasui4 and H Ohdan1
KRAS mutations occur in 30–40% of all cases of human colorectal cancer (CRC). However, to date, speciﬁc therapeutic agents
against KRAS-mutated CRC have not been developed. We previously described the generation of mouse models of colon cancer
with and without Kras mutations (CDX2P-G22Cre;Apcﬂox/ﬂox; LSL-KrasG12D and CDX2P-G22Cre;Apcﬂox/ﬂox mice, respectively). Here, the
two mouse models were compared to identify candidate genes, which may represent novel therapeutic targets or predictive
biomarkers. Differentially expressed genes in tumors from the two mouse models were identiﬁed using microarray analysis, and
their expression was compared by quantitative reverse transcription–PCR (qRT–PCR) and immunohistochemical analyses in mouse
tumors and surgical specimens of human CRC, with or without KRAS mutations, respectively. Furthermore, the functions of
candidate genes were studied using human CRC cell lines. Microarray analysis of 34 000 transcripts resulted in the identiﬁcation of
19 candidate genes. qRT–PCR analysis data showed that four of these candidate genes (Clps, Irx5, Bex1 and Rcan2) exhibited
decreased expression in the Kras-mutated mouse model. The expression of the regulator of calcineurin 2 (RCAN2) was also observed
to be lower in KRAS-mutated human CRC. Moreover, inhibitory function for cancer cell proliferation dependent on calcineurin was
indicated with overexpression and short hairpin RNA knockdown of RCAN2 in human CRC cell lines. KRASmutations in CRC lead to a
decrease in RCAN2 expression, resulting in tumor proliferation due to derepression of calcineurin–nuclear factor of activated T cells
(NFAT) signaling. Our ﬁndings suggest that calcineurin–NFAT signal may represent a novel molecular target for the treatment of
KRAS-mutated CRC.
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INTRODUCTION
It is widely known that mutations in the Kirsten rat sarcoma viral
oncogene homolog (KRAS) gene occur in the early stages of the
adenoma–adenocarcinoma sequence in human colorectal cancer
(CRC) development.1 KRAS, along with the neuroblastoma rat
sarcoma viral oncogene homolog (NRAS) and Harvey rat sarcoma
viral oncogene homolog (HRAS) genes, is a member of the RAS
gene family. KRAS and NRAS, which have been shown to exhibit
somatic mutations in 30–40% and 2–5% of human CRCs,
respectively,2–4 are known predictors for resistance to treatment
with anti-epidermal growth factor receptor antibodies.5–8
Although these biomarkers have enabled the development of
individualized therapies, especially for the treatment of CRCs with
wild-type RAS, speciﬁc therapeutic agents against RAS-mutated
CRC have not yet been established. RAS mutations cause
oncogenic activation independent of epidermal growth factor–
epidermal growth factor receptor signal transmission, resulting in
a lack of response to anti-epidermal growth factor receptor
antibodies.9 To overcome this resistance mechanism, the
identiﬁcation of downstream molecules that show potential as
new therapeutic targets for RAS-mutated CRC has become an
important focus.
Calcineurin, which was ﬁrst cloned in neural cells as a Ca2+- and
calmodulin-dependent serine/threonine protein phosphatase,10–12
dephosphorylates nuclear factor of activated T cells (NFAT). NFAT
subsequently translocates into the nucleus, where it acts as a
transcription factor that promotes various cellular activities.13–15
Calcineurin is widely distributed and its role has been character-
ized in various organs, including the myocardium,15–17 skeletal
muscle16 and lymphocytes.15,18 Its immunological function has
been studied extensively, and calcineurin inhibitors (CNIs), such as
cyclosporine A and tacrolimus, are widely used for immuno-
suppression.19–21 However, little is known about the contribution
of calcineurin to CRC, although previous reports have indicated
the oncogenic function of calcineurin: cycolooxgenase-2 and
prostaglandin E2 are induced by the pharmacological stimulation
of the Ca2+–calcineurin–NFAT signaling pathway in CRC cell
lines,22 and the expression of calcineurin A speciﬁcally increases in
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human CRCs, resulting in the activation of phosphatase activity of
calcineurin.23,24
We have previously developed mouse models in which sporadic
colon cancers were generated via the colonic epithelium-speciﬁc
inactivation of adenomatous polyposis coli (Apc), with and without
the activation of Kras, using the loxP/Cre system.25–28 Gene
expression proﬁling of the two mouse models revealed that Glut-1,
which is upregulated in KRAS-mutated human CRC cell lines,29 is
also upregulated in tumors in Kras-mutated mouse models relative
to mice carrying the wild-type Kras gene.28 This result conﬁrmed
the validity of expression proﬁling in our mouse models and
demonstrated its potential utility for the analysis of downstream
targets of the KRAS mutation in CRC.
In the current study, we aimed to identify new molecular targets
for the development of therapeutic agents against KRAS-mutated
CRC, using microarray data to compare gene expression between
mouse models with and without colonic epithelium-speciﬁc Kras
mutation. We identiﬁed a novel gene, regulator of calcineurin 2
(RCAN2), that was found to be downregulated in the tumors in
Kras-mutated mouse models, which may inhibit calcineurin
enzyme activity in CRC and exhibit tumor suppressor function.
Here we report that KRAS mutation may promote cancer cell
proliferation by decreasing the expression of RCAN2, and that
calcineurin and NFAT signaling may serve as potential therapeutic
targets for KRAS-mutated CRC.
RESULTS
Identiﬁcation of genes with altered expression in response to
mutation by microarray analysis
Genes that showed differential expression in the microarray
analysis were identiﬁed by analysis of fold change and P-values. As
genes with increased expression were previously reported by
Kawaguchi et al.,28 we focused on downregulated genes. We
analyzed 34 000 transcripts and found that the expression of 19
genes was signiﬁcantly downregulated in tumors from Kras-
mutated mice compared with those from Kras wild-type mice
(Table 1). We set the fold change ﬁlter to 5.0 and the P-value at
o0.05. Quantitative reverse transcription–PCR primers were
designed for 9 of the 19 genes. The expression of four genes,
namely Clps, Irx5, Bex1 and Rcan2, was conﬁrmed to be decreased
in the Kras-mutated mouse group compared with the wild-type
group (Figure 1).
KRAS mutations are signiﬁcantly associated with RCAN2
expression in human CRC
Immunohistochemical staining (IHC) analysis of human CRC
specimens revealed that RCAN2 was speciﬁcally expressed only
in cancer cells but not in normal colonic epithelia, adenomas or
tumor stroma (Figure 2a). Moreover, RCAN2 showed higher
expression at the invasive front (IF) of tumors (deﬁned as tumor
cells or clusters within 500 μm of the IF) than at the tumor centers
(Figures 2b–d).
Subsequently, we performed IHC to investigate the correlation
between KRAS mutation and RCAN2 expression at the IF in early-
stage human CRC specimens, as it is known that KRAS mutations
occur relatively early during multistep carcinogenesis and that
RCAN2 is potentially activated by various unknown stimuli. A total
of 62 CRC specimens that did not involve the muscularis propria
were genotyped by direct sequencing. KRAS mutations were
identiﬁed in specimens from 24 patients (38.7%), and the
remaining 38 specimens carried the wild-type KRAS gene
(61.3%). Upon further analysis, a lower frequency of IHC-positive
cells and a lower IHC-positive rate (cutoff 420%) were observed
in specimens from patients with KRAS-mutated tumors
(corresponding P-values 0.0447 and 0.362, respectively;
Figures 2e–g and Table 2), whereas other clinicopathological
characteristics were comparable between positive and negative
expression of RCAN2 (Table 2). Furthermore, the correlation
between RCAN2 expression at the IF of the tumor and other
markers, including Ki-67, p53, CDX2 and VEGF-A, was studied by
IHC. Ki-67 was upregulated with decreased expression of RCAN2 in
the KRAS-mutated CRC, and there was no association between
RCAN2 expression and the expression of other markers, except
Ki-67 (representative image is shown in Figure 3).
Effect of overexpression on cancer cell proliferation and migration
We analyzed the effect of RCAN2 expression on cancer cell
proliferation and migration by overexpressing RCAN2 in CRC cell
lines. RKO (BRAF-mutated) and SW837 (KRAS-mutated) cells with low
endogenous RCAN2 mRNA levels (Supplementary Information 1)
were infected with a retrovirus containing the pDON-5/RCAN2
vector for overexpression of RCAN2 or an empty vector (pDON-5) as
a control. Quantitative reverse transcription–PCR revealed that
RCAN2 was overexpressed in both cell lines infected with the
pDON-5/RCAN2 vector (Figure 4a). Moreover, we observed
decreased phosphatase activity of calcineurin in RKO and SW837
cell lines in which RCAN2 was overexpressed (Figure 4b). The
Table 1. Gene expression proﬁling using microarray analysis for Kras wild-type and Kras-mutated mouse models (downregulated genes)
Gene symbol Gene title Fold change Function
S100g S100 calcium binding protein G 57.23 Calcium-binding protein
Clps Colipase, pancreatic 19.96 Co-enzyme
Irx5 Iroquois related homeobox 5 (Drosophila) 11.49 Homeobox gene
Defa5 Defensin, alpha, 5 10.55 Antimicrobial peptide
Svopl SV2-related protein homolog (rat)-like 10.43 Transmembrane transporter
Sox11 SRY box-containing gene 11 9.83 Transcription factor
Iapp Islet amyloid polypeptide 9.63 Peptide hormone
Sox17 SRY box-containing gene 17 9.50 Transcription factor
Alx3 Aristaless-like homeobox 3 8.58 Homeobox gene
Gbx2 Gastrulation brain homeobox 2 7.97 Homeobox gene
Shh Sonic hedgehog 7.91 Growth factor
H19 H19 fetal liver mRNA 7.79 Long noncoding RNA, regulating cell proliferation
Ceacam10 Carcinoembryonic antigen-related cell adhesion molecule 10 7.11 Cell adhesion molecule
Rcan2 Regulator of calcineurin 2 6.28 Signaling molecule regulating calcineurin activity
Bex1 Brain expressed gene 1 6.23 Signaling adapter molecule
Asprv1 Aspartic peptidase, retroviral-like 1 5.93 Aspartic protease
Nrcam Neuron-glia-CAM-related cell adhesion molecule 5.92 Cell adhesion molecule
Wnt10a Wingless related MMTV integration site 10a 5.72 Growth factor
Slc30a2 Solute carrier family 30 (zinc transporter), member 2 5.09 Zinc transporter
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proliferation and wound-scratch migration assays performed using
the IncuCyte Zoom system (Essen BioScience, Ann Arbor, MI, USA)
revealed that cell proliferation was signiﬁcantly suppressed in the
pDON-5/RCAN2 group compared with the pDON-5 groups in both
cell lines; however, no signiﬁcant differences in migration activity
were observed (Figures 4c–f).
Effect of RCAN2 shRNA knockdown on cancer cell proliferation and
migration
Colo320 cells (both KRAS and BRAF wild-type) with relatively high
endogenous RCAN2 mRNA levels (Supplementary Information 1)
were infected with retroviruses containing two short hairpin RNA
(shRNA) vectors (pSUPER/RCAN2 shRNA1 and 2) or a non-silencing
(pSUPER/non-silencing shRNA) vector. In cell lines infected with
pSUPER/RCAN2, efﬁcient knockdown of RCAN2 was conﬁrmed
(Figure 5a). We also conﬁrmed increased phosphatase activity of
calcineurin in Colo320 cell lines infected with pSUPER/RCAN2
(Figure 5b). The proliferation and wound-scratch assays revealed
that proliferation was signiﬁcantly enhanced in both RCAN2 shRNA
groups compared with the non-silencing groups; however, no
signiﬁcant differences in migration activity were observed
(Figures 5c and d). These results suggest that RCAN2 represses
the proliferation of cancer cells, but does not affect migration
activity.
RCAN2 knockdown promotes xenograft tumor growth
In order to further investigate the impact of RCAN2 on
tumorigenesis, we implanted Colo320 cells infected with
pSUPER/RCNA2 shRNA1 and pSUPER/non-silencing shRNA into
nude mice (n= 8 for each group). Tumor growth was observed
signiﬁcantly earlier in the pSUPER/RCAN2 group than in the
pSUPER/non-silencing group (Figure 5e). Tumor weights were
signiﬁcantly higher in the pSUPER/RCAN2 group than in the
pSUPER/non-silencing group (Figures 5f and g; pSUPER/RCAN2;
147 mg vs pSUPER/non-silencing; 31 mg, P= 0.013). These
results indicate that RCAN2 silencing plays an important role
in promoting cell proliferation during colorectal tumorigenesis
in vivo.
RCAN2 function is dependent on the calcineurin pathway
In order to conﬁrm that the function of RCAN2 is dependent on
the calcineurin–NFAT pathway, Colo320 cells infected with both
pSUPER/RCAN2 shRNA1 and pSUPER/non-silencing shRNA were
treated with a CNI, cyclosporine A (0.1 μM) or tacrolimus (0.5 μM).
Proliferation in the pSUPER/RCAN2 group was repressed by
treatment with cyclosporine A in accordance with decreased
enzyme activity, whereas cyclosporine A did not have an effect in
pSUPER/non-silencing (Figures 6a and b). For tacrolimus, the
difference in proliferation between pSUPER/RCAN2 and pSUPER/
non-silence groups disappeared after treatment with tacrolimus.
Moreover, although enzyme activity was decreased in both groups
to a lower level than that in the pSUPER/non-silencing group
without any treatment, proliferation was repressed in an enzyme
activity-dependent manner (Figures 6c and d). These results
suggest that the function of RCAN2 is dependent on the
calcineurin–NFAT pathway.
DISCUSSION
In this study, following microarray analysis of tissue samples from
the two mouse models and subsequent validation by quantitative
reverse transcription–PCR, four candidate genes were identiﬁed as
Figure 1. Comparison of gene expression in tumors from Kras wild-type and Kras-mutated mouse models using quantitative reverse
transcription–PCR (qRT–PCR). Relative expression of Rcan2 normalized to B2m was compared between Kras wild-type and Kras-mutated mouse
models using qRT–PCR. Left bar; CDX2P9.5-G22Cre;Apcﬂox/ﬂox;LSL-KrasG12D mice (n= 3), Right bar; CDX2P9.5-G22Cre;Apcﬂox/ﬂox;LSL-KrasG12D mice
(n= 3). Data are expressed as means+s.d. (error bars) of triplicate experiments showing relative expression of Rcan2 normalized to that of B2m.
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Figure 2. Immunohistochemical analyses of RCAN2 in surgical specimens from patients with colorectal cancer (CRC). Representative images of
immunohistochemical staining (IHC) at the border between adenoma (right, in a) and adenocarcinoma (left, in a), and the intratumoral
distribution of RCAN2 expression (b). Magniﬁed views at the tumor center and the invasive front of tumors (c, d, respectively).
Representative IHC images of KRAS wild-type and KRAS-mutated human CRC tissue samples (e, f, respectively). Comparison of IHC-positive
cells in the carcinomatous area of KRAS wild-type and KRAS-mutated CRC indicated lower expression of RCAN2 in KRAS-mutated CRC
(P= 0.0447, g).
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potential downstream targets of oncogenic mutated KRAS. Of
these four candidates, we focused on RCAN2, an endogenous
calcineurin regulator, as increased expression of calcineurin has
been reported in human CRC by IHC analyses and comprehensive
protein expression proﬁling using antibody microarrays.23,24
Moreover, cyclosporine A, which is a known speciﬁc inhibitor of
calcineurin, has been reported to inhibit the proliferation of CRC
cell lines (HT29 and Wider) by regulating c-Myc, p21(WAF1/CIP1),
and proliferating cell nuclear antigen in a dose-dependent
manner.30 Therefore, the calcineurin–NFAT pathway was
hypothesized to have an important role in human CRC. To date,
the association between oncogenic mutated KRAS and calcineurin
signaling has not been described. To our knowledge, the current
study is the ﬁrst report that oncogenic mutated KRAS and
calcineurin signaling are associated via changes in the expression
of RCAN2.
RCAN2 was ﬁrst cloned as a thyroid hormone-responsive gene,
ZAKI-4, from human ﬁbroblasts.31 This family of genes includes
ZAKI-4, Down syndrome critical region 1 (DSCR1),32 and Down
syndrome critical region 1 like-2 (DSCR1L2),33 which share 61–68%
identity in amino acid sequence.33 These genes have been
demonstrated to inhibit calcineurin activity by binding the
catalytic subunit of calcineurin.33–36 This gene family, whose
members are collectively known as regulators of calcineurin
(RCAN), comprises RCAN1, RCAN2 and RCAN3 (previously known as
DSCR1, ZAKI-4 and DSCR1L2, respectively). RCAN2 has three
transcriptional variants and two protein isoforms; RCAN2 transcript
variant α encodes isoform-α and transcript variants β1 and β2
encode isoform-β. Both isoforms have identical C-terminals and
different N-terminals. The α-transcripts are present only in the
brain, whereas β-transcripts are ubiquitous but most abundant in
the brain, heart, skeletal muscle and kidneys. The expression of
α-transcripts, but not that of β-transcripts, is promoted by the
thyroid hormone.37,38 In the present study, quantitative reverse
transcription–PCR using primers speciﬁc for both the α- and
β-transcripts of RCAN2 was performed (data not shown), but only
β-transcripts were observed to be expressed in mouse colonic
epithelium and tumors.
The functions of genes in the RCAN family have been studied in
endothelial cells. Except for the RCAN1-1L isoform, which
promotes angiogenesis, the overexpression of RCAN1-4, RCAN2
and RCAN3 in human umbilical vein endothelial cells has been
reported to inhibit cell proliferation and migration.39–41 A
correlation between RCAN2 and bone turnover,42 obesity43 and
response to anabolic steroid administration44 has also been
reported in organs in which its expression is abundant; however,
to date, the correlation between RCAN2 and cancer has not been
studied. Moreover, the contribution of other members of the RCAN
family to cancer development is not well-known. A few studies
have reported that RCAN1 is expressed in tumor vessels, but not in
tumor cells, in renal and ovarian cancers.39,45 Our ﬁnding that
RCAN2 is speciﬁcally expressed in human CRC and has an
inhibitory role in cancer cell proliferation is therefore novel.
IHC staining revealed that RCAN2 was expressed mainly at the
tumor IF in tumor cells and that the expression of this gene was
repressed by oncogenic mutation of KRAS in human CRC.
However, the reasons for the predominance of RCAN2 expression
at the IF remain unclear. One possibility is that RCAN2 may
predominantly be expressed in highly proliferative cells, which are
located at the IF, as part of a negative feedback loop. However,
Ki-67, known as a marker of cell proliferation, was repressed
simultaneously with RCAN2 expression, indicating that this
hypothesis was incorrect. Another possibility is that interstitial
interactions may affect expression. Gene expression proﬁle
comparisons between KRAS wild-type and KRAS-mutated CRC in
cultured cell lines revealed that RCAN2 expression does not
decrease in KRAS-mutated CRC. However, a decrease in the
expression of this gene was observed in our mouse models,
those are thought to be conserved in terms of the cancer
microenvironment. This ﬁnding supports the hypothesis that
interstitial interactions may inﬂuence RCAN2 expression. Moreover,
RCAN2 was predominantly expressed at the IF, even in mucosal
adenocarcinoma or adenocarcinoma with slight submucosal
invasion, where cancer cells and the interstitium share a margin.
Although further investigation of the correlation between
expression in cancer cells and in the interstitium is required, our
results suggested that RCAN2 is predominantly expressed at the IF
and that KRAS-mutated CRC may promote tumor development
due to decreased expression of RCAN2.
The present study has some limitations. First, the molecular
mechanism by which mutated KRAS decreases the expression of
RCAN2 remains unclear. Although KRASG12V mutation and KRASG12V
mutation with effector domain mutation46 were induced in CRC
cell lines (such as Colo320 and Caco-2) containing wild-type KRAS
and BRAF alleles, these mutations did not lead to decreased
expression of RCAN2 (data not shown). The microenvironment
may affect RCAN2 expression, and further studies are required in
which RCAN2 expression is compared in mouse models with colon
epithelial cell-speciﬁc inactivation of APC and activation of other
molecules downstream of KRAS, including BRAF, PI3K and RALGDS.
Second, although the results of our functional studies of RCAN2
suggest that RCAN2 expression represses cell proliferation by
inhibiting calcineurin phosphatase activity, a previous report
suggested that cyclosporine A inhibits the growth of a colon
Table 2. Comparison of clinicopathological characteristics between
positive and negative RCAN2 expression in human colorectal cancer
RCAN2 (positive: 420%) P-value
Positive
(N= 32)
Negative
(N=30)
KRAS status (n)
Wild-type 24 14 0.0362
Mutant 8 16
Age(years)
Median (range) 71 (45–86) 68 (40–96) 0.174
Sex
Male 17 15 1
Female 15 15
Tumor location
Right sided 23 24 0.558
Left sided 9 68 (40–96)
Histologic type
Papillary 5 5 0.989
Well differentiated 18 17
Moderate
differentiated
9 8
Vascular invasion
Absent 27 27 0.709
Present 5 3
Lymphatic invasion
Absent 26 26 0.733
Present 6 4
Nodal metastasis
Absent 30 27 0.733
Present 2 3
Abbreviations: KRAS, Kirsten rat sarcoma viral oncogene homolog; RCAN2,
regulator of calcineurin 2.
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Figure 3. Immunohistochemical analyses of RCAN2 and other markers at invasive front of cancer. Representative IHC images of KRAS wild-type
(a–e) and KRAS-mutated (f–j) human CRC tissue samples, stained with anti-RCAN2 (a, f), anti-Ki-67 (b, g), anti-CDX2 (c, h), anti-VEGF-A (d, i), and
anti-p53 (e, j) antibodies.
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cancer cell line independent of the calcineurin pathway and that
tacrolimus promotes tumor growth despite efﬁcient inhibition of
NFAT activity.47 In the present study, we utilized CNIs to conﬁrm
that the tumor suppressor function of RCAN2 is dependent on the
calcineurin–NFAT pathway. For cyclosporine A, growth inhibition
was observed only in Colo320 cell lines with RCAN2 shRNA
knockdown, and not in Colo320 cell lines without RCAN2
knockdown. For tacrolimus, although both enzyme activity and
proliferation were repressed by the treatment, proliferation was
repressed in an enzyme activity-dependent manner. Therefore, we
consider that our results support the tumor suppressor function of
RCAN2. However, our ﬁndings represent only one of the various
potential mechanisms for tumor growth in KRAS-mutated CRC.
For instance, when considering CNIs as a targeted therapeutic
agent for KRAS-mutated CRC, the impact of immunosuppression
on tumor development should be considered. However, some
agents such as cyclophosphamide, methotrexate and everolimus
are known as immunosuppressant and chemotherapeutic drugs.
Dosage might be important because these agents act as
immunosuppressants at lower doses, whereas they act as
chemotherapeutic drugs at higher doses. In vivo experiments
using mouse models are expected to be useful to address this
issue. We have already developed a genome-engineered mouse
model that sporadically generates colon cancers with the Kras
mutation. This model could be used to evaluate the effect of CNI
on both CRC and the immune system when administering CNIs in
various dosages.
In conclusion, KRAS mutation in CRC leads to decreased
expression of RCAN2, resulting in tumor proliferation by
derepression of the calcineurin–NFAT signaling pathway. The
RCAN2–calcineurin–NFAT pathway may potentially serve as a
novel molecular target for the development of therapeutic agents
against KRAS-mutated CRC and should be further investigated
using the previously described mouse models of sporadic colon
cancer.
MATERIALS AND METHODS
Animal experiments
All animal experiments were approved by the University Committee on the
Use and Care of Animals of Hiroshima University and performed according
to Japanese regulations based on the 1964 Declaration of Helsinki
Principles and its later amendments. All mice were housed under speciﬁc
pathogen-free conditions. Four or ﬁve mice were housed per cage with
chopped wood bedding, and sufﬁcient food and water (with 10.0 mg/l of
Figure 4. Overexpression of RCAN2 in RKO and SW837 human colorectal cancer cell lines. RKO (BRAF-mutated) and SW837 (KRAS-mutated) cells
showing weak expression of RCAN2 were infected with RCAN2/pDON-5 and pDON-5/empty retroviruses. RCAN2 expression (a) and calcineurin
activity (b) were compared between cells infected with RCAN2/pDON-5 and pDON-5/empty (black and white bars, respectively). Proliferation
and migration were compared in RKO cells with or without RCAN2 overexpression (c, d, respectively) and SW837 cells with or without RCAN2
overexpression (e, f, respectively).
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chlorine) were supplied in each cage. The breeding room was maintained
at a constant temperature of 23± 2 °C, relative humidity of 50 ± 5%, with
15–20 air changes per hour, and a 12-h light/dark cycle with lights on at
0800 hours. Necropsy and tumor removal for tumorigenesis experiments
were performed after killing with intraperitoneal injection of pentobarbital
followed by cervical dislocation.
Gene expression proﬁling
We used microarray data previously obtained by Kawaguchi et al.28 from a
comparison between the two mouse models CDX2P9.5-G22Cre;Apcﬂox/ﬂox;
LSL-KrasG12D (C57BL/6J) and CDX2P9.5-G22Cre;Apcﬂox/ﬂox;Kras wild-type
(C57BL/6J). Brieﬂy, the 9.5-kb promoter sequence of CDX2 exhibits
transcriptional activity speciﬁcally in the mouse colonic epithelium.
Therefore, we used the transgene CDX2P9.5-G22Cre for colonic
epithelium-speciﬁc inactivation of Apc and activation of Kras via the
loxP/Cre system. In the mouse models, a 22-guanine nucleotide tract (G22)
that alters the reading frame was inserted and activated stochastically in
the mouse intestinal tract, producing a microsatellite-unstable phenotype.
Colon cancers were generated at the proximal colon and cecum, with
minimal morphological differences between the two mouse models. At the
age of 6–8 weeks, 3 tumors were collected from each of the 2 mouse
models and gene expression proﬁles of 34 000 transcripts were generated
using microarrays (GeneChip Mouse Genome 430 2.0 Array; Affymetrix,
Figure 5. shRNA knockdown of RCAN2 in the Colo320 human colorectal cancer cell line. RCAN2 expression in Colo320 cells (both KRAS and
wild-type BRAF) with high expression of RCAN2 was knocked down using an shRNA vector. RCAN2 expression (a) and calcineurin activity
(b) were compared between cells infected with pSUPER/RCAN2 1, 2 and pSUPER/non-silencing. These cells were subjected to proliferation
and wound-scratch migration assays (c, d, respectively). In vivo tumorigenesis was compared between Colo320 cells infected with
pSUPER/RCAN2 1 and pSUPER/non-silencing using a xenograft subcutaneous transplantation model in order to determine tumor volume (e)
and tumor weight (f). Images of harvested tumors are shown in g.
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Santa Clara, CA, USA). The microarray data are available in the NCBI GEO
database (Accession number: GSE75435)
Quantitative reverse transcription–PCR
Complementary DNA was generated using a QuantiTect Reverse
Transcription Kit (Qiagen, Hilden, Germany) and ampliﬁed using a Rotor-
Gene Q 2PLEX HRM Real-Time PCR system (Qiagen). The quantitative PCR
reactions, which were prepared to a ﬁnal volume of 25 μl, included 2×
Rotor-Gene SYBR Green PCR Mix (Qiagen), 10 μmol/l forward/reverse
primers, and 32 ng of each complementary DNA sample. The ampliﬁcation
protocol involved denaturation at 95 °C for 5 min, followed by 40 cycles at
95 °C for 5 s and 60 °C for 10 s. Beta-2-microglobulin (B2M) was used
as an internal control. The primers used are shown in 'Supplementary
Information 2'.
Tissue samples
Formalin-ﬁxed parafﬁn-embedded human CRC specimens, those were
obtained from the patients who had undergone colectomy at Hiroshima
University Hospital between 2006 and 2011, were used for KRAS
genotyping an IHC analyses. Of these, specimens that did not involve
the muscularis propria were included. Comprehensive approvals for basic
or clinical research were obtained from all of the patients. Experiments
using human subjects were performed in accordance with the Ethical
Guidelines for Human Genome/Gene Research set forth by the Japanese
Government, and the study was performed with the permission of the
Ethics Committee of Hiroshima University.
KRAS genotyping
For human CRC specimens, DNA was extracted from formalin-ﬁxed,
parafﬁn-embedded tumor tissue sections using TaKaRa DEXPAT (Takara
Bio Inc., Shiga, Japan). Exon 2 of KRAS was ampliﬁed by PCR, and the
products were directly sequenced using an ABI 3130 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s
instructions.
IHC staining
A Dako LSAB Kit (Dako) was used for IHC analysis. Sections were pretreated
by microwave treatment in citrate buffer for 15 min to retrieve antigenicity.
After peroxidase activity was blocked with 3% H2O2–methanol for 10 min,
sections were incubated with normal goat serum (Dako) for 20 min to
block non-speciﬁc antibody-binding sites. Sections were incubated with
the following primary antibodies: anti-RCAN2 (Thermo Scientiﬁc, Rockford,
IL, USA; diluted 1:500), anti-Ki-67 (clone MIB-1; Dako, Carpinteria, CA, USA;
diluted 1:50), anti-CDX2 (clone AMT28; BioGenex, San Ramon, CA, USA;
diluted 1:20), anti-VEGF-A (Santa Cruz Biotechnologies, Santa Cruz, CA,
USA; diluted 1:50), and anti-p53 (clone DO-7; Novocastra, Newcastle, UK;
diluted 1:50). Sections were incubated with primary antibody for 1 h at
25 °C, followed by incubation with biotinylated anti-rabbit or anti-mouse
immunoglobulin G and peroxidase-labeled streptavidin for 10 min each.
Staining was completed with a 10-min incubation in substrate–chromogen
solution. The sections were counterstained with 0.1% hematoxylin.
Appropriate positive and negative control samples were also stained.
Figure 6. Proliferation assay in Colo320 cells, with or without RCAN2 shRNA knockdown, following calcineurin inhibitor treatment. Colo320
cells infected with pSUPER/RCAN2 shRNA1 and pSUPER/non-silencing shRNA were cultured in medium with or without either cyclosporine A
or tacrolimus, and cell proliferation (a, c, respectively) and enzyme activity (b, d, respectively) were subsequently analyzed. Black line:
pSUPER/RCAN2 shRNA1 without treatment; gray line: pSUPER/RCAN2 shRNA1 with calcineurin inhibitors; black dashed line: pSUPER/
non-silencing shRNA without treatment; black dashed line: pSUPER/non-silencing shRNA with calcineurin inhibitors. CsA, cyclosporine A;
FK506, tacrolimus.
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Cell lines
All other cell lines were obtained from the American Type Culture
Collection (ATCC) between 1998 and 2000. The amphotropic Phoenix
packaging cell line was provided by G. Nolan (Stanford University,
Stanford, CA, USA). Details of cell culture conditions were previously
described.48
Plasmid construction
In brief, a 732-bp fragment of the RCAN2 coding sequence was ampliﬁed
by PCR using complementary DNA from a normal colonic epithelium and
then inserted into the retroviral vector pDON-5 neo (TaKaRa) to generate
the pDON-5/RCAN2 vector for overexpression of RCAN2. Hairpin-loop
oligonucleotides targeting RCAN2 (Supplementary Information 2) and a
non-silencing sequence were synthesized and inserted into pSUPER.retro.
neo+gfp (OligoEngine, Seattle, CA, USA) to generate ‘pSUPER/RCAN2
shRNA1, 2 and ‘pSUPER/non-silencing shRNA’. All plasmid products were
veriﬁed by sequencing.
Retroviral infection
The Phoenix packaging cells were transfected with the retroviral
constructs; the supernatant containing nonreplicating amphotropic retro-
viruses was collected. For RCAN2 overexpression, RKO (BRAF-mutated) and
SW837 (KRAS-mutated) cell lines were infected with retroviruses containing
pDON-5/RCAN2 and pDON-5 empty vectors. For RCAN2 silencing, the
Colo320 cell line (wild type for both KRAS and BRAF) was infected
with retroviruses containing pSUPER/RCAN2 shRNA1, 2 and pSUPER/non-
silencing shRNA vectors. Cells were selected using Geneticin (G418) at
concentrations of 1000, 750 and 750 μg/ml for RKO, SW837 and Colo320
cells, respectively, for 2 weeks.
Cellular proliferation and migration assay
Cell proliferation and wound-scratch migration were measured using a
brightﬁeld image label-free high-content time-lapse assay system
(IncuCyte Zoom system; Essen BioScience) according to the manufacturer’s
instructions. In brief, for the proliferation assay, equal numbers of cells
(1 × 105/well) were seeded on to 24-well plates in the appropriate culture
medium with supplements or agents, and percent cell conﬂuence was
then continuously measured using the IncuCyte system over a 5-day
period. For the migration assay, cells (1.2 × 105 cells/well) were seeded on
to 96-well ImageLock tissue culture plates (Essen BioScience) pre-
incubated with type I collagen. Once cells reached 490% conﬂuence,
at 12 h after seeding, wound scratches were made using a 96-pin
WoundMaker (Essen BioScience) and relative wound densities were
measured using the IncuCyte system over a 5-day period.
In vivo tumorigenesis assay
Five-week-old female BALB/cA Jcl-nu mice (CLEA Japan, Tokyo, Japan)
were used for the in vivo tumorigenesis assay. According to the guide line
for the welfare and use of animals in cancer research,49 sample size for
animal expreiments were determined as eight mice in each group. A total
of 1.0 × 107 Colo320 cells containing a retrovirus expressing RCAN2 shRNA1
or non-silencing shRNA were subcutaneously injected into the right ﬂanks
of eight nude mice in each group. Neither randomization nor blinding for
animal use were performed because we commercially obtained these mice
with the same genetic background. Tumor size was measured using
Vernier calipers every 2 days (from day 8 to day 16) after cell implantation.
Tumor volume was calculated using the formula: V = 0.5 a × b2, where a
represents the long diameter and b the short diameter of the tumor.
Tumors were removed from the mice and weighed on day 16.
Calcineurin activity assay
Calcineurin activity was measured using a calcineurin cellular activity assay
(Enzo Life Sciences, Farmingdale, NY, USA) according to the manufacturer’s
instructions. Extracted cell lysates were centrifuged at 100 000 g for 45 min
at 4 °C and the supernatant was placed in a desalting column to remove
excess phosphates and nucleotides. Total phosphatase activity was
assessed in the samples by incubating with a phosphopeptide substrate.
Calcium-independent phosphatase activity was assessed in the samples by
incubating samples with EGTA and a phosphopeptide substrate.
The resulting total phosphatase activity was subtracted from the
calcium-independent phosphatase activity to determine calcineurin
activity levels.
Treatment of cells with CNIs
Cyclosporine A and tacrolimus were purchased from Novartis Pharma
Japan and Astellas Pharma Japan, respectively. For the proliferation assay,
cells were cultured in medium supplemented with 0.1 μM cyclosporine A or
0.5 μM tacrolimus until the end of the IncuCyte proliferation assay.
To conﬁrm the suppression of calcineurin activity under the treatment
with cyclosporine A and tacrolimus, cell lysates were extracted 96 h after
treatment with CNIs and calcineurin activity was compared between
extracted cell lines with or without the treatment of CNIs.
Statistical analysis
All experiments were repeated at least three times with each sample in
triplicate. Sample sizes for relevant experiment were determined by power
analysis. All values are expressed as means± s.d. The statistical signiﬁcance
of differences was determined using the Student’s t-test, Mann–Whitney
U-test, or Fisher’s exact test. A two-tailed P-value of o0.05 was considered
statistically signiﬁcant. All statistical analyses were performed using JMP 10
software (SAS Institute Inc., Cary, NC, USA) and R statistical software version
R2.10.0 (R Foundation for Statistical Computing, Vienna, Austria).
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